Created in 1997, Hybrigenics is a bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: - alone in chronic lymphocytic leukaemia - in combination with imatinib in chronic myeloid leukaemia - in prostate cancer, for use with current standards of care Hybrigenics' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells.
Type
Public
HQ
Paris, FR
Founded
1998
Size (employees)
55 (est)
Hybrigenics was founded in 1998 and is headquartered in Paris, FR
Report incorrect company information

Key People/Management at Hybrigenics

Jean-Francois DUFOUR-LAMARTINIE

Jean-Francois DUFOUR-LAMARTINIE

Senior Director, Head of Clinical R&D
Guillaume Floch

Guillaume Floch

Chief Financial Officer
Valerie MANDON

Valerie MANDON

Human Resources Director
Remi DELANSORNE

Remi DELANSORNE

Chairman and CEO
Alain Munoz

Alain Munoz

Strategy Committee Chairman
Albert Saporta

Albert Saporta

Independent Director
Show more

Hybrigenics Office Locations

Hybrigenics has an office in Paris
Paris, FR (HQ)
3-5 impasse Reille
Show all (1)
Report incorrect company information

Hybrigenics Financials and Metrics

Hybrigenics Financials

Market capitalization (31-Oct-2017)

20.4 m

Closing share price (31-Oct-2017)

0.6
Hybrigenics's current market capitalization is €20.4 m.
Show all financial metrics
Report incorrect company information